How fast is Intuitive Surgical growing, and is revenue becoming more concentrated?

Sales rose 94% to $51.7M in 2001, mainly because system unit sales increased from 28 to 49. Revenue is still lumpy because each system carries a high price, and one distributor, AB Medica SRL, accounted for 15% of 2001 sales. Management also expects a limited number of new customers to account for a large share of future revenue.

When might Intuitive reach profitability, and how much cash does it need?

The company expects significant operating losses for at least two more years and says it may never reach profitability. It had $66.7M in cash and short-term investments at year-end 2001 after burning $18.6M in operations. Management believes this is enough through 2003, but may need to raise equity or debt after that, which could dilute shareholders.

What is the biggest legal risk to the investment thesis?

Computer Motion's California suit alleges infringement of nine robotic surgery patents and seeks damages (including treble damages) and an injunction. Intuitive's counterclaim-related interference proceedings are expected to be decided around April 2002, and the Delaware IBM-backed case is scheduled for trial in Q3 2002. A loss could require a license on unfavorable terms, a redesign, or a halt to sales, and the company says it cannot estimate the possible loss.

What regulatory and reimbursement hurdles remain?

The da Vinci system is cleared for laparoscopic, non-cardiac thoracoscopic, and laparoscopic prostatectomy procedures, but cardiac uses (mitral valve repair, atrial septal defect closure, totally endoscopic CABG) still require additional trials and 510(k) submissions. Reimbursement is generally available for existing approved procedures, but a new CPT code could take two or more years if needed. International sales depend on CE mark maintenance and Japanese approvals that are still in progress.

Are the margins improving enough to support future growth?

Gross margin improved to 45% in 2001 from 32% in 2000, aided by manufacturing efficiencies and higher volume, and excluding the IBM royalty it would have been 47%. However, SG&A grew 57% and R&D rose 18%, and management expects both to keep increasing as the sales force and clinical programs expand. Operating leverage will depend on continued sales growth outpacing those expense increases.

ISRG 10-K FY2001 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed April 1, 2002. Cited figures are marked; the original filing is the authoritative source.

Intuitive Surgical's 2001 10-K shows a company still in early commercialization of its da Vinci Surgical System.

Revenue more than doubled to $51.7 million^a in 2001 from $26.6 million in 2000, driven by system sales rising to 49 units from 28. Gross margin improved to 45% from 32%, helped by manufacturing efficiencies, though the company still posted a net loss of $16.7 million (EPS of -$0.47), narrowing from $18.5 million in 2000. Operating expenses grew 42% to $43.8 million as selling, general and administrative costs rose 57% to $30.0 million to build out the sales and field service organization.

The balance sheet is thinner than the headline numbers suggest. Cash, equivalents and short-term investments fell to $66.7 million^b from $89.4 million, and operating cash burn was $18.6 million. Management states that current resources are sufficient through 2003, but it also warns that additional financing may be needed afterward.

Accounts receivable jumped to $13.2 million^c, a sign that revenue growth is consuming working capital. The main investor risk is litigation. Computer Motion's suit (which seeks treble damages and an injunction) and Brookhill-Wilk's appeal could threaten the company's ability to sell its products if the company loses.

Several of these matters are unresolved, and the company says it cannot estimate potential losses. Regulatory progress is also a key variable: the FDA clearances obtained so far cover laparoscopic, thoracoscopic, and prostatectomy use, while cardiac indications remain under investigation.

02—Key points

Key Highlights

Revenue grew 94% to $51.7M in 2001, with system unit sales rising to 49 from 28 in 2000.
Gross margin expanded to 45% (from 32%), though it was reduced by a $1.0M non-routine IBM royalty charge.
Net loss narrowed to $16.7M (-$0.47/share) from $18.5M, but the accumulated deficit reached $110.4M and management expects losses for at least two more years.
Cash and short-term investments declined to $66.7M from $89.4M, and operating cash outflow was $18.6M; management says resources are sufficient through 2003.
Concentrated litigation risk: Computer Motion seeks damages (including treble damages) and an injunction, with PTO interference decisions expected around April 2002 and the Delaware trial set for Q3 2002.
Regulatory position: FDA clearances cover laparoscopic surgery, non-cardiac thoracoscopy, and laparoscopic radical prostatectomy; trials for mitral valve repair, ASD closure, and totally endoscopic CABG are ongoing.
Installed base is still small (89 systems sold cumulatively through 2001), and 34% of 2001 sales came from outside the U.S., with about 15% from a single distributor (AB Medica).

03—Questions

Frequently Asked Questions

How fast is Intuitive Surgical growing, and is revenue becoming more concentrated?
Sales rose 94% to $51.7M in 2001, mainly because system unit sales increased from 28 to 49. Revenue is still lumpy because each system carries a high price, and one distributor, AB Medica SRL, accounted for 15% of 2001 sales. Management also expects a limited number of new customers to account for a large share of future revenue.
When might Intuitive reach profitability, and how much cash does it need?
The company expects significant operating losses for at least two more years and says it may never reach profitability. It had $66.7M in cash and short-term investments at year-end 2001 after burning $18.6M in operations. Management believes this is enough through 2003, but may need to raise equity or debt after that, which could dilute shareholders.
What is the biggest legal risk to the investment thesis?
Computer Motion's California suit alleges infringement of nine robotic surgery patents and seeks damages (including treble damages) and an injunction. Intuitive's counterclaim-related interference proceedings are expected to be decided around April 2002, and the Delaware IBM-backed case is scheduled for trial in Q3 2002. A loss could require a license on unfavorable terms, a redesign, or a halt to sales, and the company says it cannot estimate the possible loss.
What regulatory and reimbursement hurdles remain?
The da Vinci system is cleared for laparoscopic, non-cardiac thoracoscopic, and laparoscopic prostatectomy procedures, but cardiac uses (mitral valve repair, atrial septal defect closure, totally endoscopic CABG) still require additional trials and 510(k) submissions. Reimbursement is generally available for existing approved procedures, but a new CPT code could take two or more years if needed. International sales depend on CE mark maintenance and Japanese approvals that are still in progress.
Are the margins improving enough to support future growth?
Gross margin improved to 45% in 2001 from 32% in 2000, aided by manufacturing efficiencies and higher volume, and excluding the IBM royalty it would have been 47%. However, SG&A grew 57% and R&D rose 18%, and management expects both to keep increasing as the sales force and clinical programs expand. Operating leverage will depend on continued sales growth outpacing those expense increases.

04—Continue

← View all 10-K filings